WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou
FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access
WuXi PharmaTech Receives Honorable Mention at 2014 ISPE Facility of the Year Awards
See below for other press releases by year.
2018 2017 2016 2015 2014 2013 2012